Home/Filings/4/0001062993-21-012387
4//SEC Filing

Maricich Yuri 4

Accession 0001062993-21-012387

CIK 0001835567other

Filed

Dec 6, 7:00 PM ET

Accepted

Dec 7, 5:23 PM ET

Size

21.4 KB

Accession

0001062993-21-012387

Insider Transaction Report

Form 4
Period: 2021-12-03
Maricich Yuri
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-12-03+103,068103,068 total
    Exercise: $1.09Exp: 2030-03-24Common Stock (103,068 underlying)
  • Award

    Class A Common Stock

    2021-12-03+73,62073,620 total
  • Award

    Stock Option (Right to Buy)

    2021-12-03+44,17244,172 total
    Exercise: $0.68Exp: 2027-12-13Common Stock (44,172 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-12-03+103,068103,068 total
    Exercise: $0.72Exp: 2028-03-21Common Stock (103,068 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-12-03+73,62073,620 total
    Exercise: $0.02Exp: 2025-05-05Common Stock (73,620 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-12-03+176,689176,689 total
    Exercise: $0.14Exp: 2026-05-10Common Stock (176,689 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-12-03+88,34488,344 total
    Exercise: $1.08Exp: 2029-03-14Common Stock (88,344 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-12-03+220,862220,862 total
    Exercise: $1.29Exp: 2031-01-26Common Stock (220,862 underlying)
Footnotes (12)
  • [F1]Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for 50,000 shares of common stock of Private Pear previously held by Mr. Maricich.
  • [F10]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.60 per share.
  • [F11]25% of the shares underlying the option vested or shall vest on January 26, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
  • [F12]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 150,000 shares of common stock of Private Pear for $1.89 per share.
  • [F2]100% of the shares subject to this option are fully vested and exercisable.
  • [F3]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 50,000 shares of common stock of Private Pear for $0.02 per share.
  • [F4]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 30,000 shares of common stock of Private Pear for $1.00 per share.
  • [F5]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 120,000 shares of common stock of Private Pear for $0.20 per share.
  • [F6]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.05 per share.
  • [F7]25% of the shares underlying the option vested or shall vest on March 14, 2020 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
  • [F8]Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 60,000 shares of common stock of Private Pear for $1.58 per share.
  • [F9]25% of the shares underlying the option vested or shall vest on March 24, 2021 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.

Issuer

Pear Therapeutics, Inc.

CIK 0001835567

Entity typeother

Related Parties

1
  • filerCIK 0001881045

Filing Metadata

Form type
4
Filed
Dec 6, 7:00 PM ET
Accepted
Dec 7, 5:23 PM ET
Size
21.4 KB